Flipping the script on chronic immune diseases

Hundreds of millions of patients around the world suffer from chronic autoimmune and inflammatory diseases such as multiple sclerosis, type 1 diabetes, alopecia areata, psoriasis and inflammatory bowel disease.

We believe that our transformative approach to in vivo immune cell engineering has the potential to achieve something completely audacious... durable or even curative therapy.

Patients need Cures

Immune diseases are chronic, debilitating, and affect the quality of life of hundreds of millions of people worldwide. A diagnosis brings life-changing challenges to patients and their families. Each patient's journey is unique, but they share something powerful in common... the desire for a cure. We stand beside patients on their journey in search of cures.

Current Therapies Fall Short

While the best standard-of care therapies can provide much needed relief, they don't work for everyone, and they come with potentially severe side effects and safety risks. Even in the best case, patients are left with lifelong treatment and a significant financial burden. They might win the battle, but not the war.

Restoring Balance is the Key to Cures

Restoring immune system homeostasis and balance at the site of inflammation is the key to unlocking cures for patients. Our transformative technology is designed specifically to overcome the limitations of current therapies, both reducing inflammation and increasing suppressive capacity right in the affected tissue.

Our Science

T cells are a shared driver across multiple autoimmune and inflammatory diseases, responsible for immune mediated tissue destruction through the action of inflammatory cytokines or by direct cell-to-cell killing. Our novel, best-in-class approach reprograms these pathogenic T cells into homeostatic anti-inflammatory cells that restore balance and resolve inflammation for the long term. This powerful strategy both reduces the number of local pathogenic cells, and reconstitutes protective immune cells right where they are needed most. We apply the latest technologies and insights to our work, encoding our proprietary payloads into inherently safe mRNA that is delivered by cutting-edge LNP technology.

We are leading the way towards curative therapies with our groundbreaking approach to in vivo immune cell reprogramming.

Get in touch to learn more about our mission or to explore collaboration or investment opportunities.

Get in Touch

our team

Meet our team of experienced and savvy drug developers, immunologists, engineers, business developers and corporate leaders.

Dave Pajerowski, PhD
Co-Founder, CEO (Head of Technology)

Dave is a committed scientist and biotechnologist that has been bringing innovative new investigational therapies to the clinic for nearly 15 years. He is a former technology leader at Cambridge area biotechs Repertoire Immune Medicines and Nvelop Therapeutics, and led the PhI / PhII technical development of Moderna's Personalized Cancer Vaccine. He got his industry start at Merck and Co., working in bioprocessing and manufacturing sciences. His PhD is in Bioengineering from the University of Pennsylvania. Dave's mission is to turn sci-fi bio concepts into real medicines.

Mathias Pawlak, PhD
Co-Founder, CSO (Head of Biology)

Mathias is an accomplished immunologist and molecular biologist. He performed his PhD with Rudolf Jaenisch at the Whitehead Institute/MIT and trained as a postdoctoral fellow with Vijay Kuchroo at Harvard Medical School/Brigham and Women's Hospital. Mathias has made important contributions to the fields of epigenetics, autoimmunity, inflammation and immuno-oncology. He has led programs and teams at small and medium sized biotech companies, including being a program lead at BlueRock Therapeutics, (wholly owned by Bayer) and VP, Head of Platform Research at Portal Biotechnologies. Developing medicines for patients with devastating diseases is what drives Mathias every day.

Anis Gammage DPhil
Co-Founder (Fractional)

Anis is an immunologist and experienced company creator, having contributed to the spin-out of multiple biotech companies from venture studio Deep Science Ventures. He is currently Pharma scoping lead at Deep Science Ventures, and previously supported immunology and epigenetic drug development programs at UCB Pharma and Boehringer Ingelheim.